Please login to the form below

Not currently logged in


This page shows the latest camizestrant news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca’s two advanced breast cancer trials meet primary endpoints

AstraZeneca’s two advanced breast cancer trials meet primary endpoints

SERENA-2 is a randomised, open-label, parallel group, multicentre phase 2 trial evaluating camizestrant at 75mg and 150mg dose levels compared to Faslodex 500mg in post-menopausal patients with oestrogen ... in patients with ER-driven breast cancer and

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts


Add my company

Fox&cat is a new kind of fully-integrated communications agency – one that delivers genuinely inspirational campaigns and programmes with equal...

Latest intelligence

Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
Humancomms for humancare?
Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...